S&P 500 Rises 0.5%; Crude Oil Falls Sharply
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection.
Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19.
Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the
Recap: Adamis Pharmaceuticals Q2 Earnings
Adamis Pharmaceuticals (NASDAQ:ADMP) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Adamis Pharmaceuticals Q2 EPS $(0.06) Misses $(0.03) Estimate
Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is unchanged from the same period last year.
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: